Current challenges in the management of invasive fungal infections

Journal of Infection and Chemotherapy

Volumn 14, Issue 2, 2008, Pages 77-85

  Lai, Chih Cheng ^a   Tan, Che Kim ^b   Huang, Yu Tsung ^c   Shao, Pei Lan ^d   Hsueh, Po Ren ^d  

^a Yi Min Hospital   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Epidemiology; Invasive fungal infections; Treatment

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FUNGAL DNA; GALACTOMANNAN; GENOMIC DNA; GLUCAN; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; RAVUCONAZOLE; STEROID; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ABSIDIA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CELL WALL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CUNNINGHAMELLA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DNA DETERMINATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; EARLY DIAGNOSIS; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FOOD; FOOD DRUG INTERACTION; FUNGAL CELL; FUNGEMIA; FUNGICIDAL ACTIVITY; FUSARIUM; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; KIDNEY FAILURE; LABORATORY DIAGNOSIS; LIPID DIET; LIVER FAILURE; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MONOTHERAPY; MORTALITY; MUCORMYCOSIS; MYCOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; REVIEW; RHIZOMUCOR; RHIZOPUS; TREATMENT OUTCOME;

EID: 43049141529     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-007-0595-7     Document Type: Review

References (139)

1. G.S. Martin D.M. Mannino S. Eaton M. Moss The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 2003 1546 1554
2. T.A. Clark R.A. Hajjeh Recent trends in the epidemiology of invasive mycoses Curr Opin Infect Dis 17 2004 511 515
3. M.A. Pfaller P.G. Pappas J.R. Wingard Invasive fungal pathogens: current epidemiological trends Clin Infect Dis 43 Suppl1 2006 S3 S14
4. A.M. Tortorano C. Kibbler J. Peman H. Bernhardt L. Klingspor R. Grillot Candidaemia in Europe: epidemiology and resistance Int J Antimicrob Agents 27 2006 359 366
5. S.Y. Ruan L.N. Lee J.S. Jerng C.J. Yu P.R. Hsueh Candida glabrata fungaemia in intensive care units Clin Microbiol Infect 2007 [Epub ahead of print]
6. P.R. Hsueh L.J. Teng P.C. Yang S.W. Ho K.T. Luh Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole Microb Drug Resist 8 2002 311 319
7. L. Ostrosky-Zeichner P.G. Pappas Invasive candidiasis in the intensive care unit Crit Care Med 34 2006 857 863
8. P. Eggimann J. Garbino D. Pittet Epidemiology of Candida species infections in critically ill non-immunosuppressed patients Lancet Infect Dis 3 2003 685 702
9. P.G. Pappas J.H. Rex J. Lee R.J. Hamill R.A. Larsen W. Powderly A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients Clin Infect Dis 37 2003 634 643
10. R.A. Hajjeh A.N. Sofair L.H. Harrison G.M. Lyon B.A. Arthington-Skaggs S.A. Mirza Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program J Clin Microbiol 42 2004 1519 1527
11. M. Nucci K.A. Marr Emerging fungal diseases Clin Infect Dis 41 2005 521 526
12. K.C. Hazen New and emerging yeast pathogens Clin Microbiol Rev 8 1995 462 478
13. T.A. Clark S.A. Slavinski J. Morgan B.A. Arthington-Skaggs M.E. Brandt R.M. Webb Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital J Clin Microbiol 42 2004 4468 4472
14. D.M. Kuhn P.K. Mikherjee T.A. Clark C. Pujol J. Chandra R.A. Hajjeh Candida parapsilosis characterization in an outbreak setting Emerg Infect Dis 10 2004 1074 1081
15. E. Sarvikivi O. Lyytikainen D.R. Soll C. Pujol M.A. Pfaller M. Richardson Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit J Clin Microbiol 43 2005 2729 2735
16. C.A. Kauffman Fungal infections in older adults Clin Infect Dis 33 2001 550 555
17. M.A. Pfaller D.J. Diekema Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility J Clin Microbiol 40 2002 3551 3557
18. D.J. Diekema S.A. Messer A.B. Brueggemann S.L. Coffman G.B. Doern L.A. Herwaldt Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study J Clin Microbiol 40 2002 1298 1302
19. M.A. Pfaller D.J. Diekema R.N. Jones S.A. Messer R.J. Hollis Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000 J Clin Microbiol 40 2002 852 856
20. A. Malani J. Hmoud L. Chiu P.L. Carver A. Bielaczyc C.A. Kauffman Candida glabrata fungemia: experience in a tertiary care center Clin Infect Dis 41 2005 975 981
21. M.S. Rangel-Frausto T. Wiblin H.M. Blumberg L. Saiman J. Patterson M. Rinaldi National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units Clin Infect Dis 29 1999 253 258
22. L. Saiman E. Ludington M. Pfaller S. Rangel-Frausto R.T. Wiblin J. Dawson Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group Pediatr Infect Dis J 19 2000 319 324
23. D. Abi-Said E. Anaissie O. Uzun I. Raad H. Pinzcowski S. Vartivarian The epidemiology of hematogenous candidiasis caused by different Candida species Clin Infect Dis 24 1997 1122 1128
24. K.A. Marr K. Seidel T.C. White R.A. Bowden Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole J Infect Dis 181 2000 309 316
25. J. Baran Jr. B. Muckatira R. Khatib Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital Scand J Infect Dis 33 2001 137 139
26. D.P. Kontoyiannis I. Vaziri H.A. Hanna M. Boktour J. Thornby R. Hachem Risk factors for Candida tropicalis fungemia in patients with cancer Clin Infect Dis 33 2001 1676 1681
27. J.R. Wingard Importance of Candida species other than C. albicans as pathogens in oncology patients Clin Infect Dis 20 1995 115 125
28. M.A. Pfaller D.J. Diekema M.G. Rinaldi R. Barnes B. Hu A.V. Veselov Results from the ARTEMIS DISK global antifungal surveillance study: a 6.5-year analysis of the worldwide susceptibility of Candida and other yeasts species to fluconazole and voriconazole using standardized disk diffusion testing J Clin Microbiol 43 2005 5848 5859
29. W.E. Trick S.K. Fridkin J.R. Edwards R.A. Hajjeh R.P. Gaynes Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999 Clin Infect Dis 35 2002 627 630
30. A. Antoniadou H.A. Torres R.E. Lewis J. Thornby G.P. Bodey J.P. Tarrand Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy Medicine (Baltimore) 82 2003 309 321
31. W. Hope A. Morton D.P. Eisen Increase in prevalence of nosocomial non- Candida albicans candidaemia and the association of Candida krusei with fluconazole use J Hosp Infect 50 2002 56 65
32. M.A. Pfaller D.J. Diekema Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida . International Fungal Surveillance Participant Group Clin Microbiol Infect 10 Suppl1 2004 11 23
33. L. Ostrosky-Zeichner J.H. Rex P.G. Pappas R.J. Hamill R.A. Larsen H.W. Horowitz Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States Antimicrob Agents Chemother 47 2003 3149 3154
34. M.A. Pfaller S.A. Messer L. Boyken R.J. Hollis C. Rice S. Tendolkar In vitro activities of voriconazole, posaconazole, and fluconazole against 4169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program Diagn Microbiol Infect Dis 48 2004 201 205
35. M.A. Pfaller S.A. Messer L. Boyken C. Rice S. Tendolkar R.J. Hollis Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3000 clinical isolates J Clin Microbiol 42 2004 3117 3119
36. M.A. Pfaller S.A. Messer R.J. Hollis R.N. Jones D.J. Diekema In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6970 clinical isolates of Candida spp Antimicrob Agents Chemother 46 2002 1723 1727
37. K.A. Marr R.A. Carter F. Crippa A. Wald L. Corey Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients Clin Infect Dis 34 2002 909 917
38. T.F. Patterson W.R. Kirkpatrick M. White J.W. Hiemenz J.R. Wingard B. Dupont Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group Medicine (Baltimore) 79 2000 250 260
39. F.M. Marty S.J. Lee M.M. Fahey E.P. Alyea R.J. Soiffer J.H. Antin Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study Blood 102 2003 2768 2776
40. T.F. Patterson Advances and challenges in management of invasive mycoses Lancet 366 2005 1013 1025
41. R.A. Hajjeh D.W. Warnock Counterpoint: invasive aspergillosis and the environment – rethinking our approach to prevention Clin Infect Dis 33 2001 1549 1552
42. D.J. Diekema S.A. Messer R.J. Hollis R.N. Jones M.A. Pfaller Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi J Clin Microbiol 41 2003 3623 3626
43. P.C. Iwen M.E. Rupp A.N. Langnas E.C. Reed S.H. Hinrichs Invasive pulmonary aspergillosis due to Aspergillosis terreus : 12-year experience and review of the literature Clin Infect Dis 26 1998 1092 1097
44. W.J. Steinbach D.K. Benjamin Jr. D.P. Kontoyiannis J.R. Perfect I. Lutsar K.A. Marr Infections due to Aspergillus terreus : a multicenter retrospective analysis of 83 cases Clin Infect Dis 39 2004 192 198
45. J.R. Perfect G.M. Cox J.Y. Lee C.A. Kauffman L. Repentigny S.W. Chapman The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Mycoses Study Group Clin Infect Dis 33 2001 1824 1833
46. J.W. Baddley B. Park K.A. Marr D.R. Andes D.P. Kontoyiannis S. Hadley Factors influencing mortality in transplant recipients with invasive aspergillosis (abstract 673) Program and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America (Boston) 2004 The University of Chicago Press Alexandria, VA 174
47. A. Cornillet C. Camus S. Nimubona V. Gandemer P. Tattevin C. Bellequic Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey Clin Infect Dis 43 2006 577 584
48. C.C. Lai S.J. Liaw L.N. Lee C.H. Hsiao C.J. Yu P.R. Hsueh Invasive aspergillosis: high incidence of disseminated intravascular coagulation in fatal cases J Microbiol Immunol Infect 40 2007 141 147
49. M.M. Roden T. Zaoutis W.L. Buchanan T.A. Knudsen T.A. Sarkisova R.L. Schaufele Epidemiology and outcome of zygomycosis: a review of 929 reported cases Clin Infect Dis 41 2005 634 653
50. C.E. Gonzalez M.G. Rinaldi A.M. Sugar Zygomycosis Infect Dis Clin North Am 16 2002 895 914
51. B. Spellberg J. Edwards Jr. A. Ibrahim Novel perspectives on mucormycosis: pathophysiology, presentation, and management Clin Microbiol Rev 18 2005 556 569
52. R.N. Greenberg K. Mullane J.A. Burik I. Raad M.J. Abzug G. Anstead Posaconazole as salvage therapy for zygomycosis Antimicrob Agents Chemother 50 2006 126 133
53. M. Nucci K.A. Marr F. Queiroz-Telles C.A. Martins P. Trabasso S. Costa Fusarium infection in hematopoietic stem cell transplant recipients Clin Infect Dis 38 2004 1237 1242
54. M. Nucci E.J. Anaissie F. Queiroz-Telles C.A. Martins P. Trabasso C. Solza Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection Cancer 98 2003 315 319
55. M. Nucci E. Anaissie Fusarium infections in immunocompromised patients Clin Microbiol Rev 20 2007 695 704
56. S.F. Yeo B. Wong Current status of nonculture methods for diagnosis of invasive fungal infections Clin Microbiol Rev 15 2002 465 484
57. A. Ulusakarya E. Chachaty J.M. Vantelon A. Youssef C. Tancrede J.L. Pico Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies Hematol J 1 2000 111 116
58. M.A. Mennink-Kersten J.P. Donnelly P.E. Verweij Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis Lancet Infect Dis 4 2004 349 357
59. P.L. Shao L.M. Huang P.R. Hsueh Invasive fungal infection-laboratory diagnosis and antifungal treatment J Microbiol Immunol Infect 39 2006 178 188
60. C.C. Lai H.L. Hsu L.N. Lee P.R. Hsueh Assessment of Platelia Aspergillus enzyme immunoassay for the diagnosis of invasive aspergillosis J Microbiol Immunol Infect 40 2007 148 153
61. Z. Odabasi G. Mattiuzzi E. Estey H. Kantarjian F. Saeki R.J. Ridge Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome Clin Infect Dis 39 2004 199 205
62. T.F. Patterson Advances and challenges in management of invasive mycoses Lancet 366 2005 1013 1025
63. L. Ostrosky-Zeichner B.D. Alexander D.H. Kett J. Vazque P.G. Paappas F. Saeki Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans Clin Infect Dis 41 2005 654 659
64. D. Buchheidt M. Hummel D. Schleiermacher B. Spiess R. Schwerdtfeger O.A. Cornely Prospective clinical evaluation of a Light Cycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients Br J Haematol 125 2004 196 202
65. B. Spiess D. Buchheidt C. Baust H. Skladny W. Seifarth U. Zeilfelder Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients J Clin Microbiol 41 2003 1811 1818
66. C. Costa J.M. Costa C. Desterke F. Botterel C. Cordonnier S. Bretagne Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis J Clin Microbiol 40 2002 2224 2227
67. W.E. Dismukes Introduction to antifungal drugs Clin Infect Dis 30 2000 653 657
68. D.W. Bates L. Su D.T. Yu G.M. Chertow D.L. Seger D.R. Gomes Mortality and costs of acute renal failure associated with amphotericin B therapy Clin Infect Dis 32 2001 689 693
69. J.M. Poirier G. Cheymol Optimisation of itraconazole therapy using target drug concentrations Clin Pharmacol 35 1998 461 473
70. E.K. Manavathu J.L. Cutright P.H. Chandrasekar Organism-dependent fungicidal activities of azoles Antimicrob Agents Chemother 42 1998 3018 3021
71. A.H. Groll S.C. Piscitelli T.J. Walsh Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development Adv Pharmacol 44 1998 343 500
72. H.W. Boucher A.H. Groll C.C. Chiou T.J. Walsh Newer systemic antifungal agents: pharmacokinetics, safety and efficacy Drugs 64 2004 1997 2020
73. L.B. Johnson C.A. Kauffman Voriconazole: a new triazole antifungal agent Clin Infect Dis 36 2003 630 637
74. L. Purkins N. Wood P. Ghahramani K. Greenhalgh M.J. Allen D. Kleinermans Pharmacokinetics and safety of voriconazole following intravenous to oral dose escalation regimens Antimicrob Agents Chemother 46 2002 2546 2553
75. D. Leveque Y. Niviox F. Jehl R. Herbrecht Clinical pharmacokinetics of voriconazole Int J Antimicrob Agents 27 2006 274 284
76. G.M. Keating Posaconazole Drugs 65 2005 1553 1567
77. P. Krieter B. Flannery T. Musick M. Gohdes M. Martinho R. Courtney Disposition of posaconazole following single-dose oral administration of posaconazole in healthy subjects Antimicrob Agents Chemother 48 2004 3543 3551
78. J.R. Perfect K.A. Marr T.J. Walsh R.N. Greenberg B. DuPont J. Torre-Cisneros Voriconazole treatment for less common, emerging, or refractory fungal infections Clin Infect Dis 36 2003 1122 1131
79. A.H. Groll H. Kolve Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy Eur J Microbiol Infect Dis 23 2004 256 270
80. H.K. Munayyer P.A. Mann A.S. Chau T. Yarosh-Tomaine J.R. Greene R.S. Hare Posaconazole is a potent inhibitor of sterol 14α-demethylation in yeasts and molds Antimicrob Agents Chemother 48 2004 3690 3696
81. N.I. Paphitou L. Ostrosky-Zeichner V.L. Paetznick J.R. Rodriguez E. Chen J.H. Rex In vitro antifungal susceptibilities of Trichosporon species Antimicrob Agents Chemother 46 2002 1144 1146
82. A. Espinel-Ingroff Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743, 872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts J Clin Microbiol 36 1998 2950 2956
83. A.L. Barry S.D. Brown In vitro studies of two triazole antifungal agents (voriconazole [UK-104xxx496] and fluconazole) against Candida species Antimicrob Agents Chemother 40 1996 1948 1949
84. C.A. Kauffman L.T. Zarins In vitro activity of voriconazole against Candida species Diagn Microbiol Infect Dis 31 1998 297 300
85. F. Barchiesi D. Arzeni A.W. Fothergill L.F. Francesco F. Caselli M.G. Rinaldi In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens Antimicrob Agents Chemother 44 2000 226 229
86. J.R. Perfect G.M. Cox R.K. Dodge W.A. Schell In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans Antimicrob Agents Chemother 40 1996 1910 1913
87. M.A. Pfaller S.A. Messer L. Boyken C. Rice S. Tendolkar R.J. Hollis Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004) J Clin Microbiol 43 2005 2163 2167
88. A. Espinel-Ingroff In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12052 fungal isolates: review of the literature Rev Iberoam Micol 20 2003 121 136
89. A.K. Zaas M. Boyce W. Schell B.A. Lodge J.L. Miller J.R. Perfect Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates J Clin Microbiol 41 2003 5233 5255
90. K.L. Oakley C.B. Moore D.W. Denning In vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B J Antimicrob Chemother 42 1998 91 94
91. E.K. Manavathu J.L. Cutright D. Loebenberg D.H. Chandrasekar A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole, and posaconazole (SCH-56592) J Antimicrob Chemother 46 2000 229 234
92. C.J. Clancy M.H. Nguyen In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species Eur J Clin Microbiol Infect Dis 17 1998 573 575
93. A.J. Carrillo J. Guarro In vitro activities of four novel triazoles against Scedosporium spp Antimicrob Agents Chemother 45 2001 2151 2153
94. A. Safdar Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus : rapid response to treatment with caspofungin and itraconazole Clin Infect Dis 34 2002 1415 1417
95. M.A. Pfaller S.A. Messer R.J. Hollis R.N. Jones Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobiol Surveillance Program, 2000 Antimicrob Agents Chemother 46 2002 1032 1037
96. G.M. Gonzalez A.W. Fothergill D.A. Sutton M.G. Rinaldi D. Loebenberg In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi Med Mycol 43 2005 281 284
97. G.M. Gonzalez R. Tijerina L.K. Najvar R. Bocanegra M. Rinaldi D. Loebenberg In vitro and in vivo activities of posaconazole against Coccidioides immitis Antimicrob Agents Chemother 46 2002 1352 1356
98. R.K. Li M.A. Ciblak N. Nordoff L. Pasarell D.W. Warnock M.R. McGinnis In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis , and Histoplasma capsulatum Antimicrob Agents Chemother 44 2000 1734 1736
99. A. Gomez-Lopez M. Cuenca-Estrella A. Monzon J.L. Rodriquez-Tudela In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B flucytosin, itraconazole, and voriconazole J Antimicrob Chemother 48 2001 919 921
100. E. Dannaoui J. Meletiadis J.W. Mouton J.F. Meis P.E. Verweij In vitro susceptibilities of zygomycetes to conventional and new antifungals J Antimicrob Chemother 51 2003 45 52
101. Q.N. Sun A.W. Fothergill D.I. McCarthy M.G. Rinaldi J.R. Graybill In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes Antimicrob Agents Chemother 46 2002 1581 1582
102. R. Herbrecht D.W. Denning T.F. Patterson J.E. Bennett R.E. Greene J.W. Oestmann Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 2002 408 415
103. D.W. Denning P. Ribaud N. Milpied D. Caillot R. Herbrecht E. Thiel Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 34 2002 563 571
104. T.J. Walsh P. Pappas D.J. Winston H.M. Lazarus F. Petersen J. Raffalli Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 2002 225 234
105. R. Ally D. Schurmann W. Kreisel G. Carosi K. Aguirrebengoa B. Dupont A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients Clin Infect Dis 33 2001 1447 1454
106. L. Ostrosky-Zeichner A.M.L. Oude-Lashof B.J. Kullberg J.H. Rex Voriconazole salvage treatment of invasive candidiasis Eur J Clin Microbiol Infect Dis 22 2003 651 655
107. J. Garbino I. Uckay P. Rohner D. Lew C. Delden Fusarium peritonitis concomitant to kidney transplantation successfully managed with voriconazole: case report and review of the literature Transplant Int 18 2005 613 618
108. S. Consigny N. Dhedin A. Datry S. Choquet V. Leblond O. Chosidow Successful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient Clin Infect Dis 37 2003 311 313
109. N. Asada H. Uryu M. Koseki M. Takeuchi M. Komatsu K. Matsue Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia Clin Infect Dis 43 2006 e39 e41
110. T.J. Walsh I. Raad T.F. Patterson P. Chandrasekar G.R. Donowitz R. Graybill Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial Clin Infect Dis 44 2007 2 12
111. O.A. Cornely J. Maertens D.J. Winston J. Perfect A.J. Ullmann T.J. Walsh Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 2007 348 359
112. A.J. Ullmann J.H. Lipton D.H. Vesole P. Chandrasekar A. Langston S.R. Tarantolo Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease N Engl J Med 356 2007 335 347
113. L.B. Johnson C.A. Kauffman Voriconazole: a new triazole antifungal agent Clin Infect Dis 36 2003 630 637
114. A.H. Groll T.J. Walsh Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections Expert Opin Investig Drugs 61 2001 1545 1548
115. D.W. Denning Echinocandin antifugal drugs Lancet 362 2003 1142 1151
116. P.H. Chandrasekar J.D. Sobel Micafungin: a new echinocandin Clin Infect Dis 42 2006 1171 1178
117. J.A. Stone S.D. Holland P.J. Wickersham A. Sterrett M. Schwartz C. Bonfiglio Single-and multiple-dose pharmacokinetics of caspofungin in healthy men Antimicrob Agents Chemother 46 2002 739 745
118. J.A. Vazquez J.D. Sobel Anidulafungin: a novel echinocandin Clin Infect Dis 43 2006 215 222
119. D.S. Krause J. Reinhardt J.A. Vazquez A. Reboli B.P. Goldstein M. Wible Phase 2, randomized, dose ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia Antimicrob Agents Chemother 48 2004 2021 2024
120. S.K. Balani X. Xu B.H. Arison M.V. Silva A. Gries F.A. DeLuna Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine Drug Metab Dispos 28 2000 1274 1278
121. Caspofungin acetate. FDA Advisory Committee meeting background. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3676b1_02.pdf (accessed Jan 28, 2007)
122. G.M. Keating D.P. Figgitt Caspofungin: a review of its use in oesophageal candidasis, invasive candidiasis and invasive aspergillosis Drugs 63 2003 2235 2263
123. J.A. Dowell W. Knebel T. Ludden M. Stogniew D. Krause T. Henkel Population pharmacokinetic analysis of andiulafungin, an echinocandin antifungal J Clin Pharmacol 44 2004 590 598
124. S. Katiyar M. Pfaller T. Edlind Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility Antimicrob Agents Chemother 50 2006 2892 2894
125. M. Hakii J.F. Staab K.A. Marr Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy Antimicrob Agents Chemother 50 2006 2522 2524
126. M. Krogh-Madsen M.C. Arendrup L. Heslet J.D. Knudsen Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient Clin Infect Dis 42 2006 938 944
127. V. Moudgal T. Little D. Boikov J.A. Vanquez Multiechinocandinand multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis Antimicrob Agents Chemother 49 2005 767 769
128. S. Park R. Kelly J.N. Kahn J. Robles M.J. Hsu E. Register Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates Antimicrob Agents Chemother 49 2005 3264 3273
129. K.L. Oakley C.B. Moore D.W. Denning In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus species Antimicrob Agents Chemother 42 1998 2726 2730
130. S. Tawara F. Ikeda K. Maki Y. Morishita K. Otomo N. Teratani In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi Antimicrob Agents Chemother 44 2000 57 62 10.1128/AAC.44.1.57-62.2000
131. S. Arikan M. Lozano-Chiu V. Paetznick J.H. Rex In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp Antimicrob Agents Chemother 46 2002 245 247
132. K. Uchida Y. Nishiyama N. Yokota H. Yamaguchi In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens J Antibiot (Tokyo) 53 2000 1175 1181
133. J. Mora-Duarte R. Betts C. Rotstein A.L. Colombo L. Thompson-Moya J. Smietana Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029
134. T.J. Walsh H. Teppler G.R. Donowitz J.A. Maertens L.R. Baden A. Dmoszynska Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 2004 1391 1402
135. J. Maertens I. Raad G. Petrikkos M. Boogaerts D. Selleslag F.B. Petersen Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy Clin Infect Dis 39 2004 1563 1571
136. D.W. Denning K.A. Marr W.M. Lau D.P. Facklam V. Ratanatharathorn C. Becker Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis J Infect 53 2006 337 349
137. J.H. Rex P.G. Pappas A.W. Karchmer J. Sobel J.E. Edwards S. Hadley National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized double blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects Clin Infect Dis 36 2003 1221 1228
138. P.K. Mukherjee D.J. Sheehan C.A. Hitchcock M.A. Ghannoum Combination treatment of invasive fungal infection Clin Microbiol Rev 18 2005 163 194
139. D.P. Kontoyiannis R. Hachem R.E. Lewis G.A. Rivero H.A. Torres J. Thornby Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies Cancer 98 2003 292 299